Pharma-biotech capex expected to exceed $13 Billion in 2006
Houston, TX —According to Industrial Information Resources, Inc. , other problems in the pharma-biotech industry haven’t deterred its capital investment. It now has nearly 300 capital projects in North America that are slated to start construction this year—in the aggregate it totals over $13 billion.
Major projects are no longer limited to big pharmaceutical companies as the biotechnology sector is on a growth trajectory. With lots of drugs awaiting regulatory approval, the sector continues to boost manufacturing capacity to accommodate product launches and for the ensuing demand for the new drugs. Along with manufacturing capacity, research laboratories continue to attract heavy capital investment, as new-development‘pipelines’ for both sectors must be continually fed.
— Richard Phelps , senior editor, Control Engineering